MTEC

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Depression, Washington Convention Center, Government, Development, Veteran, Walter, Patient, Insomnia, Concussion, TBI, Anxiety, MTEC, Chronic pain, Traumatic brain injury, Dementia, PTSD, Medical device

HOUSTON, TEXAS, March 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced it was selected and provided a poster presentation at the “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” on March 12, 2024, which was held at the Walter E. Washington Convention Center in Washington, D.C.

Key Points: 
  • The U.S. Army Medical Research and Development Command’s (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA), with support of MTEC, hosted the State of the Technology meeting focused on non-invasive neuroassessment tools.
  • This was an ideal venue for our poster presentation as the conference attendees included many of the leading thought leaders and decision-makers from both the public and private sectors.
  • Notably, both the DoD and BARDA’s concerns continue to grow surrounding TBI, and we’re seeing the US Government significantly invest in new, non-drug therapeutic options to address TBI in support of struggling warfighters and veterans.
  • We could not have been more pleased with the overwhelming response to our presentation and look forward to providing more details on our latest study in an upcoming abstract publication.”

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Retrieved on: 
Thursday, December 28, 2023
Biomedical technology, Partnership, Burn, CMC, Bromelain (pharmacology), GMP, Burns, MTEC, Pharmaceutical industry

The $14.4 million project budget will advance the development and production of a new, temperature-stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings.

Key Points: 
  • The $14.4 million project budget will advance the development and production of a new, temperature-stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings.
  • "We are delighted to further solidify our partnership with the U.S. Department of Defense.
  • The additional funding will enhance our CMC activities, expedite preclinical development, and facilitate the establishment of a GMP compliant aseptic production line for the temperature-stable formulation of NexoBrid," announced Ofer Gonen, Chief Executive Officer of MediWound.
  • In alignment with this mission, it's vital to have field solutions for severe burn treatments that are both easy-to-use and effective.

Spectral AI Announces 2023 Third Quarter Financial Results

Retrieved on: 
Monday, November 13, 2023
EBITDA, Classification, Research, Research and development, D, Pediatrics, MDAI, UKCA, Royal college, Spectral, History, Patient, Government, Burn, CE marking, Alpha (finance), FDA, Artificial intelligence, Wound healing, Podiatry, CE, Adjustment, Trial of the century, Development, Partnership, London Stock Exchange, 3D, AI, Biomedical technology, Certification, MTEC, Unitary state, DFU, Medical device, Nursing, Cryptocurrency, Pharmaceutical industry, Management

DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2023 (“Q3 2023”).

Key Points: 
  • DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2023 (“Q3 2023”).
  • As previously announced, we also expect 2024 revenue growth of approximately 60% from anticipated 2023 levels.”
    All comparisons are to the third quarter ended September 30, 2022 (“Q3 2022”) unless otherwise stated.
  • As of September 30, 2023, cash and cash equivalents totaled $7.3 million and the Company had no long-term debt.
  • The Company will host a conference call on Tuesday, November 14, 2023 at 9:00 am Eastern Time to discuss the results.

OREF, MTEC, DOD Select Recipients of $2 Million Research Award Collaboration

Retrieved on: 
Tuesday, October 24, 2023
Education, Health, ACL, Orthopaedic Research Society, Human musculoskeletal system, Musculoskeletal injury, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Army Medical Research and Development Command, Doctor of Philosophy, Research, Military medicine, Injury, Quality of life, Anterior cruciate ligament, DOD, Partnership, Woman, The Foundation for Young Australians, Defense, Patient, MTEC, Knee pain, Pharmaceutical industry, Nursing, MD, United States Army, Service

ROSEMONT, Ill., Oct. 24, 2023 /PRNewswire-PRWeb/ -- The Orthopaedic Research and Education Foundation (OREF), in collaboration with the Medical Technology Enterprise Consortium (MTEC) and the Department of Defense's (DOD) U.S. Army Medical Research and Development Command's (USAMRDC) Military Operational Medicine Research Program (MOMRP), today announced selection for recipients of the OREF/MTEC Request for Project Proposals entitled, "MTEC-23-02-MSKI, Solutions to Accelerate Return-to-Readiness following Musculoskeletal Injuries." The program provides $2 million in research and development funding. OREF is contributing $100,000 toward the awards, which was made possible by a generous gift from The Aircast Foundation, a private foundation committed to promoting and supporting excellence in scientific and clinical research and education in the area of orthopaedic medicine. The remainder of the funding is provided by the DOD.

Key Points: 
  • Recipients will utilize the funds for research leading to the advancement of solutions to accelerate return-to-readiness for Service Members experiencing musculoskeletal injuries.
  • The program provides $2 million in research and development funding.
  • OREF is excited to collaborate with MTEC and MOMRP to fund research that may accelerate return-to-readiness for Service members affected by musculoskeletal injuries."
  • "An important component of the public-private collaboration that MTEC fosters is the ability to leverage philanthropic dollars to serve military medical need.

Data Center with Passive Direct Liquid Cooling Will Utilize a Heat Reuse Scheme to Warm Up a City in Poland

Retrieved on: 
Tuesday, October 17, 2023
MTEC, Loop heat pipe, Modular data center, Ecosystem, Growth, SAN, OCP, MDC, PDLC, Green Loop, Water, Recycling

The planned data center will be built using 350kW Modular Data Centers with PDLC developed by Neurok Thermocon Inc.

Key Points: 
  • The planned data center will be built using 350kW Modular Data Centers with PDLC developed by Neurok Thermocon Inc.
  • Passive Direct Liquid Cooling appeared recently on the crossroad of multiple trends in the data center industry.
  • Loop Heat Pipes based PDLC enables sustainable data center growth and maintains an ability of heat reuse with minimal efforts.
  • Neurok Thermocon Inc. provides Passive Direct Liquid Cooling (PDLC) systems for data centers all over the world under the brand Green Loop Cooling.

MedTech Innovator Names StrokeDx as 2023 Global Competition Winner at The MedTech Conference

Retrieved on: 
Wednesday, October 11, 2023
General Health, Health Technology, Health, Medical Devices, Olympus Corporation, Medtech, Quality of life, Algorithm, Zimmer Biomet, MTEC, Stroke, Wilson Sonsini Goodrich & Rosati, Cambridge Consultants, Johnson & Johnson, Patient, SVP, Global Competitiveness Report, Feedback, American Society of Plastic Surgeons, ASPS, NAMSA, FDA, Plastic, Business development, AdvaMed, InterSystems, Growth, MTI, Conference, Pharmaceutical industry, Capgemini, Dexcom, Final

MedTech Innovator , the world’s largest accelerator of medical technology companies, today announced that StrokeDx is the winner of its 2023 Global Competition.

Key Points: 
  • MedTech Innovator , the world’s largest accelerator of medical technology companies, today announced that StrokeDx is the winner of its 2023 Global Competition.
  • From among five finalists in the 2023 cohort, the winner was determined by a live audience vote during The MedTech Conference , powered by AdvaMed, on October 10.
  • Two hundred companies were invited to pitch during the MedTech Innovator Road Tour, with 61 companies ultimately participating in the 2023 Cohort.
  • “The MedTech Innovator program has been incredible, and its impact on our company for years to come will be significant,” said Alexander Ballatori, co-founder and CEO, StrokeDx.

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Retrieved on: 
Tuesday, September 26, 2023
Defense Health Agency, U.S. Department of Defense Strategy for Operating in Cyberspace, Bromelain (pharmacology), United States Department of Defense, Temperature, Burn, United States Department of the Army, United States Army Medical Research and Development Command, Biomedical technology, MTEC, Pharmaceutical industry, Defense

The $6.5 million project budget will advance the development of a new, temperature stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings.

Key Points: 
  • The $6.5 million project budget will advance the development of a new, temperature stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings.
  • “We are honored to further our collaboration with the U.S. Department of Defense.
  • Our shared vision of enhancing treatment outcomes for traumatic burns on the battlefield will ensure NexoBrid's availability for military use,” said Ofer Gonen, Chief Executive Officer of MediWound.
  • In alignment with this mission, it's vital to have field solutions for severe burn treatments that are both easy-to-use and effective.

Immuron to present at the Military Health System Research Symposium

Retrieved on: 
Monday, August 14, 2023
Immuron, IMC, Naval Medical Research Center, Enterotoxigenic Escherichia coli, U.S. Department of Defense Strategy for Operating in Cyberspace, Diarrhea, Campylobacter, Gastroenteritis, ETEC, ASX, Traveler, Judgement, Development, IBS, Disease, NMRC, Poster, Morale, MTEC, Pharmaceutical industry

The company will attend the meeting as an Exhibitor and present two posters at the event.

Key Points: 
  • The company will attend the meeting as an Exhibitor and present two posters at the event.
  • One entitled ‘Clinical Evaluation of an Oral prophylactic for prevention of Travelers diarrhea in active-duty military assigned abroad’.
  • The Naval Medical Research Center (NMRC) are also presenting a poster at the symposium on the new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron.
  • The NMRC poster is entitled ‘Research and Development of Hyperimmune Bovine Colostrum Products for the Prevention of Travelers’ Diarrhea’.

Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma

Retrieved on: 
Thursday, June 1, 2023
Other Education, Other Health, University, Stem Cells, Pharmaceutical, Education, Philanthropy, Hospitals, Genetics, Clinical Trials, Foundation, Science, Biotechnology, Health, Research, Resuscitation, Trauma center, Partnership, DSMB, University of Texas System, Hospital, George, McGovern Medical School, 3D, Trauma, Regenerative medicine, Memorial Hermann–Texas Medical Center, Patient, Standard of care, Memorial, Pediatrics, Department of Defense Serum Repository, Texas Medical Center, Injury, MTEC, Safety, Nursing, Vaccine, Neuroscience

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma.

Key Points: 
  • Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma.
  • MATRICS-1 is supported in part by MTEC (Medical Technology Enterprise Consortium) in partnership with the Department of Defense, and funding from Memorial Hermann Foundation.
  • MultiStem’s unique mechanism of action has the potential to address the often fatal complications that occur following a severe traumatic event.
  • The MATRICS-1 double-blind, placebo-controlled Phase 2 study is evaluating the safety and effectiveness of MultiStem for the prevention and early treatment of complications after severe traumatic injury.

Spectral MD Holdings, Ltd. $4.0 Million Grant Award from the Medical Technology Enterprise Consortium

Retrieved on: 
Tuesday, April 18, 2023
Defense, Nursing, Military, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, AIM, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, Doctor of Philosophy, United States Department of Defense, Policy, Unitary state, Burn, Spectral, SMD, Government, Triage, Artificial intelligence, FDA, MTEC, News, Injury, Medical device

Spectral MD Holdings, Ltd. (AIM: SMD) (“Spectral MD” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announces today that it has received a $4 million award from the Medical Technology Enterprise Consortium (MTEC).

Key Points: 
  • Spectral MD Holdings, Ltd. (AIM: SMD) (“Spectral MD” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announces today that it has received a $4 million award from the Medical Technology Enterprise Consortium (MTEC).
  • The MTEC is a 501(c)(3) biomedical consortium collaborating with the U.S. Army Medical Material Development Activity (USAMMDA).
  • “This funding will further Spectral MD’s innovation within the burn indication and support the continued development of our handheld digital burn assessment tool.
  • We look forward to partnering with MTEC to advance our AI-driven diagnostic technology as we work toward FDA submission for the burn indication.